J. Rodriguez-Lopez

发表

Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis

T. Sundt, M. Jaff, Yuchiao Chang, 2018, Journal of Thrombosis and Thrombolysis.

A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism.

T. Sundt, M. Jaff, Yuchiao Chang, 2016, Chest.

Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension

R. Thadhani, S. Karumanchi, H. DuBrock, 2016, Pulmonary circulation.

Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia

Robert M. H. Grange, R. Kacmarek, P. Lai, 2021, Nitric Oxide.

Chronic thromboembolic pulmonary hypertension (CTEPH) on dual energy CT (DECT)

M. Kalra, S. Digumarthy, J. Shepard, 2014 .

Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium

Michael C. McDaniel, Aditya M. Sharma, Nicholas R. Teman, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Surgical Management of Acute and Chronic Pulmonary Embolism.

C. Wright, J. Rodriguez-Lopez, B. Levarge, 2018, Clinics in chest medicine.

Impact of Pulmonary Arterial Clot Location on Pulmonary Embolism Treatment and Outcomes (90 Days).

J. Giri, M. Jaff, Yuchiao Chang, 2017, The American journal of cardiology.

Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia

H. Al‐Samkari, D. Kuter, J. Rodriguez-Lopez, 2018, Journal of internal medicine.

Pulmonary Hypertension in Adult Congenital Heart Disease

J. Rodriguez-Lopez, 2014, Current Treatment Options in Cardiovascular Medicine.

Endothelin Receptor Antagonists

R. Channick, J. Rodriguez-Lopez, 2015 .

Cerebrovascular and cardiovascular disease burden in patients with hereditary hemorrhagic telangiectasia

F. Qeadan, S. Quadri, M. Farooqui, 2021, Neurological Sciences.

Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker

V. J. Kelly, A. Waxman, J. Venegas, 2022, Respiratory Research.

Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension: Insights from histopathological findings of surgical specimens

G. Vlahakes, C. Wright, R. Kradin, 2017 .

Room for improvement in pulmonary capillary wedge pressure reporting: a review of hemodynamic tracings at a large academic medical center

R. Channick, A. Witkin, J. Rodriguez-Lopez, 2020, Pulmonary circulation.

Quantifying the learning curve for pulmonary thromboendarterectomy

S. Sihag, G. Vlahakes, C. Wright, 2017, Journal of Cardiothoracic Surgery.

Pulmonary Capillary Hemangiomatosis: The Role of Invasive Cardiopulmonary Exercise Testing

H. DuBrock, R. Kradin, R. Channick, 2015, Pulmonary circulation.

Treatment of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia - a Case Series and Systematic Review.

M. Lanuti, K. Wilson, H. Farber, 2021, Pulmonary pharmacology & therapeutics.

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

V. McLaughlin, K. Chin, R. Frantz, 2022, Pulmonary circulation.

Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia

A. Mojtahed, P. Bloom, J. Luther, 2020, Clinical and translational gastroenterology.

Electric Plasma-generated Nitric Oxide: Hemodynamic Effects in Patients with Pulmonary Hypertension.

L. Berra, W. Zapol, M. Semigran, 2016, American journal of respiratory and critical care medicine.

ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine.

G. Michaud, C. Channick, C. Thomson, 2015, Annals of the American Thoracic Society.

Matthew D. Li, J. Shepard, B. Little, 2020, The Lancet Infectious Diseases.

Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia

K. Heimdal, M. Mei-Zahav, J. Piccirillo, 2020, Annals of Internal Medicine.

Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia.

E. Holbrook, A. Lin, E. Grabowski, 2023, Journal of thrombosis and haemostasis : JTH.

Increased internalization of complement inhibitor CD59 may contribute to endothelial inflammation in obstructive sleep apnea

R. Wahab, Gang Wang, M. Emin, 2016, Science Translational Medicine.

Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.

William R. Bradley, I. Bhan, Esperance A K Schaefer, 2023, The New England journal of medicine.

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

M. Mei-Zahav, V. Iyer, J. McWilliams, 2020, Haematologica.

Perfusion Imaging Distinguishes Exercise Pulmonary Arterial Hypertension at Rest.

V. J. Kelly, K. Hibbert, A. Waxman, 2019, American journal of respiratory and critical care medicine.

The Pulmonary Embolism Response Team: What Is the Ideal Model?

R. Channick, J. Rodriguez-Lopez, 2017, Seminars in Respiratory and Critical Care Medicine.

Anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia: A scoping review.

H. Al‐Samkari, J. Rodriguez-Lopez, Zain M Virk, 2023, Thrombosis research.

Elevations in Norclobazam Concentrations and Altered Mental Status in CYP2C19 Poor Metabolizer Phenotype: A Case Report

J. Rodriguez-Lopez, Kristy M. Phillips, Andrew J. Webb, 2023, The Neurohospitalist.

A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism.

T. Sundt, M. Jaff, Yuchiao Chang, 2016, Chest.